Research location

New Orleans

Louisiana, United States

Published trials1,617

Site observations2,145

Linked trials published1,617

Page1 / 33

Research activity in New Orleans

Louisiana, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 1,617 trials and 2,145 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in New Orleans

1,617 linked trials · page 1 of 33

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast CancerNCT07310420 · 2026-10-30 · 1 site observation

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · 2026-08-10 · 1 site observation

Implementation Models for Blood Pressure Monitoring in Pregnancy and Postpartum: Connected MOM PlusNCT07691541 · 2026-07-01 · 1 site observation

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)NCT07621237 · 2026-06-25 · 1 site observation

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.NCT07357597 · 2026-06-24 · 1 site observation

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23 · 1 site observation

Continuous Glucose Monitoring (CGM) in an Underserved PopulationNCT07135531 · 2026-03-19 · 1 site observation

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNCT07473778 · 2026-03-17 · 2 site observations

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 · 2026-03-16 · 1 site observation

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT07288398 · 2026-03-03 · 1 site observation

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06842498 · 2026-02-22 · 1 site observation

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsNCT07361562 · 2025-12-30 · 1 site observation

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersNCT07221851 · 2025-12-12 · 1 site observation

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · 2025-12-10 · 1 site observation

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)NCT07296484 · 2025-11-29 · 1 site observation

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · 2025-11-07 · 1 site observation

A Study of Modified Release RTN-001 In Patients With Uncontrolled HypertensionNCT07142356 · 2025-10-31 · 1 site observation

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)NCT06837181 · 2025-09-18 · 1 site observation

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 3 site observations

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)NCT07154706 · 2025-08-21 · 1 site observation

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154 · 2025-08-19 · 1 site observation

PSMA PET Combined With MRI for the Detection of PCaNCT07052214 · 2025-08-18 · 1 site observation

A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis DisparitiesNCT06428643 · 2025-08-14 · 1 site observation

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesNCT06570798 · 2025-07-16 · 1 site observation

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation

E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28 · 2 site observations

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsNCT07080242 · 2025-04-28 · 1 site observation

Multilevel Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African AmericansNCT07576595 · 2025-04-17 · 2 site observations

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635 · 2025-04-01 · 1 site observation

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598 · 2025-03-27 · 1 site observation

Remote Postpartum Blood Pressure Monitoring and Cardiovascular EducationNCT06920563 · 2025-03-17 · 1 site observation

Collaborative Multi-level Obesity Intervention Engaging Communities TrialNCT06835686 · 2025-03-14 · 1 site observation

Alleviant ALLAY-HFrEF StudyNCT06812533 · 2025-03-10 · 1 site observation

A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552 · 2025-02-26 · 1 site observation

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With GlaucomaNCT06822738 · 2025-02-11 · 1 site observation

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT06388421 · 2025-01-23 · 1 site observation

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's DiseaseNCT06680830 · 2025-01-17 · 1 site observation

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574 · 2024-12-19 · 1 site observation

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsNCT06784193 · 2024-12-16 · 1 site observation

Sacral Neuromodulation for Male Overactive Bladder (MOAB)NCT06511141 · 2024-10-22 · 1 site observation

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of HypertensionNCT06559891 · 2024-10-03 · 1 site observation

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation

Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)NCT06472206 · 2024-09-23 · 2 site observations

Global Paradise System US Post Approval StudyNCT06297291 · 2024-06-28 · 1 site observation

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)NCT06263426 · 2024-05-22 · 1 site observation

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaNCT06307665 · 2024-05-20 · 2 site observations

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.